Anti-Factor Xa–Based Anticoagulation during Extracorporeal Membrane Oxygenation: Potential Problems and Possible Solutions

Abstract

Choices for monitoring of unfractionated heparin (UFH) anticoagulation in extracorporeal membrane oxygenation (ECMO) patients include activated clotting time, activated partial thromboplastin time, reaction times of viscoelastic tests, and anti-factor Xa activity (between 0.3 and 0.7 IU/mL). Recent studies propose the anti-factor Xa to be the gold standard for monitoring UFH anticoagulation in ECMO. However, many extraneous factors combined question the utility of anti-factor Xa as the sole method of monitoring of UFH effects in ECMO. Anti-factor Xa is a chromogenic assay, which may be biased by the frequently elevated values of bilirubin and free hemoglobin in ECMO patients. The test may alternatively underestimate UFH effects in cases of low antithrombin values. More importantly, the anti-factor Xa assay is a plasma-based test which does not take into account the role of platelets and fibrinogen in forming a stable clot. Thrombocytopenia and platelet dysfunction are common features in ECMO patients, and underestimating their role may lead to over-anticoagulation, should only anti-factor Xa guiding be used to adjust the UFH dose. Conversely, fibrinogen is an acute phase protein, and some patients may experience high levels of fibrinogen during the ECMO course. In this case, an UFH monitoring based on anti-factor Xa is insensitive to this condition, although it may potentially be associated with thrombotic complications. Finally, the generally suggested range of 0.3 to 0.7 IU/mL is a somewhat arbitrary estimate, based on the desired range for treating and preventing thrombotic events in non-ECMO patients. In conclusion, anti-factor Xa may offer useful information on the real effects of UFH only when combined with a whole blood test capable of assessing the relative contribution of platelets and fibrinogen to clot formation.

Keywords

ECMO - anti-factor Xa - unfractionated heparin - viscoelastic tests

• References

• 1 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
• 2 Menk M, Briem P, Weiss B. , et al. Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support. Ann Intensive Care 2017; 7 (01) 82
• 3 Sanfilippo F, Asmussen S, Maybauer DM. , et al. Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med 2017; 32 (05) 312-319
• 4 Esper SA, Welsby IJ, Subramaniam K. , et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sang 2017; 112 (05) 443-452
• 5 Ranucci M, Baryshnikova E, Cotza M. , et al; Group for the Surgical and Clinical Outcome Research (SCORE). Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both?. Minerva Anestesiol 2016; 82 (08) 858-866
• 6 Koster A, Ljajikj E, Faraoni D. Traditional and non-traditional anticoagulation management during extracorporeal membrane oxygenation. Ann Cardiothorac Surg 2019; 8 (01) 129-136
• 7 Moynihan K, Johnson K, Straney L. , et al. Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support. Perfusion 2017; 32 (08) 675-685
• 8 Panigada M, , E Iapichino G, Brioni M. , et al. Thromboelastography-based anticoagulation management during extracorporeal membrane oxygenation: a safety and feasibility pilot study. Ann Intensive Care 2018; 8 (01) 7
• 9 Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14 (02) e77-e84
• 10 Northrop MS, Sidonio RF, Phillips SE. , et al. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med 2015; 16 (01) 66-74
• 11 O'Meara LC, Alten JA, Goldberg KG. , et al. Anti-Xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. ASAIO J 2015; 61 (03) 339-344
• 12 Irby K, Swearingen C, Byrnes J, Bryant J, Prodhan P, Fiser R. Unfractionated heparin activity measured by anti-factor Xa levels is associated with the need for extracorporeal membrane oxygenation circuit/membrane oxygenator change: a retrospective pediatric study. Pediatr Crit Care Med 2014; 15 (04) e175-e182
• 13 Liveris A, Bello RA, Friedmann P. , et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med 2014; 15 (02) e72-e79
• 14 Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med 2017; 48 (04) 295-313
• 15 Vera-Aguilera J, Yousef H, Beltran-Melgarejo D. , et al. Clinical scenarios for discordant anti-Xa. Adv Hematol 2016; 2016: 4054806
• 16 Iapichino GE, Protti A, Andreis DT. , et al. Antithrombin during extracorporeal membrane oxygenation in adults: national survey and retrospective analysis. ASAIO J 2019; 65 (03) 257-263
• 17 Nelson KM, Hansen LA, Steiner ME, Fischer GA, Dehnel J, Gupta S. Continuous antithrombin III administration in pediatric veno-arterial extracorporeal membrane oxygenation. J Pediatr Pharmacol Ther 2017; 22 (04) 266-271
• 18 Stansfield BK, Wise L, Ham III PB. , et al. Outcomes following routine antithrombin III replacement during neonatal extracorporeal membrane oxygenation. J Pediatr Surg 2017; 52 (04) 609-613
• 19 Wong TE, Nguyen T, Shah SS, Brogan TV, Witmer CM. Antithrombin concentrate use in pediatric extracorporeal membrane oxygenation: a multicenter cohort study. Pediatr Crit Care Med 2016; 17 (12) 1170-1178
• 20 Diaz R, Moffett BS, Karabinas S, Guffrey D, Mahoney Jr DH, Yee DL. Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. J Pediatr 2015; 167 (03) 645-649
• 21 Dufour N, Radjou A, Thuong M. Hemolysis and plasma free hemoglobin during extracorporeal membrane oxygenation support: from clinical implications to laboratory details. A review. ASAIO J 2020; 66 (03) 239-246
• 22 Pan KC, McKenzie DP, Pellegrino V, Murphy D, Butt W. The meaning of a high plasma free haemoglobin: retrospective review of the prevalence of haemolysis and circuit thrombosis in an adult ECMO centre over 5 years. Perfusion 2016; 31 (03) 223-231
• 23 Lyu L, Yao J, Gao G. , et al. Incidence, risk factors, and outcomes of hyperbilirubinemia in adult cardiac patients supported by veno-arterial ECMO. Artif Organs 2018; 42 (02) 148-154
• 24 Kostousov V, Nguyen K, Hundalani SG, Teruya J. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med 2014; 138 (11) 1503-1506
• 25 Khan J, Chandler WL. Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support. Artif Organs 2019 ; doi: 10.1111/aor.13467 [Epub ahead of print]
• 26 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013; 39 (03) 258-266
• 27 Kon ZN, Dahi S, Evans CF. , et al. Class III obesity is not a contraindication to venovenous extracorporeal membrane oxygenation support. Ann Thorac Surg 2015; 100 (05) 1855-1860
• 28 McCaughan GJB, Favaloro EJ, Pasalic L, Curnow J. Anticoagulation at the extremes of body weight: choices and dosing. Expert Rev Hematol 2018; 11 (10) 817-828
• 29 Isherwood M, Murphy ML, Bingham AL, Siemianowski LA, Hunter K, Hollands JM. Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients. J Thromb Thrombolysis 2017; 43 (04) 476-483
• 30 Andrew M, Marzinotto V, Massicotte P. , et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994; 35 (01) 78-83
• 31 Schechter T, Finkelstein Y, Ali M. , et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost 2012; 10 (03) 368-374
• 32 Mazzeffi M, Tanaka K. Platelets and ECMO: should we worry about count, function, or both?. Intensive Care Med 2016; 42 (07) 1199-1200
• 33 Mazzeffi M, Greenwood J, Tanaka K. , et al. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann Thorac Surg 2016; 101 (02) 682-689
• 34 Lukito P, Wong A, Jing J. , et al. Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ibα and glycoprotein VI. J Thromb Haemost 2016; 14 (11) 2253-2260
• 35 Chung JH, Yeo HJ, Kim D. , et al. Changes in the levels of beta-thromboglobulin and inflammatory mediators during extracorporeal membrane oxygenation support. Int J Artif Organs 2017; 40 (10) 575-580
• 36 Tauber H, Streif W, Fritz J. , et al. Predicting transfusion requirements during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2016; 30 (03) 692-701
• 37 Mutlak H, Reyher C, Meybohm P. , et al. Multiple electrode aggregometry for the assessment of acquired platelet dysfunctions during extracorporeal circulation. Thorac Cardiovasc Surg 2015; 63 (01) 21-27
• 38 Nair P, Hoechter DJ, Buscher H. , et al. Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. J Cardiothorac Vasc Anesth 2015; 29 (02) 288-296
• 39 Balle CM, Jeppesen AN, Christensen S, Hvas AM. Platelet function during extracorporeal membrane oxygenation in adult patients: a systematic review. Front Cardiovasc Med 2018; 5: 157
• 40 Kalbhenn J, Schlagenhauf A, Rosenfelder S, Schmutz A, Zieger B. Acquired von Willebrand syndrome and impaired platelet function during venovenous extracorporeal membrane oxygenation: rapid onset and fast recovery. J Heart Lung Transplant 2018; 37 (08) 985-991
• 41 Riley JB, Schears GJ, Nuttall GA, Oliver Jr WC, Ereth MH, Dearani JA. Coagulation parameter thresholds associated with non-bleeding in the eighth hour of adult cardiac surgical post-cardiotomy extracorporeal membrane oxygenation. J Extra Corpor Technol 2016; 48 (02) 71-78
• 42 Acharya P, Jakobleff WA, Forest SJ. , et al. Fibrinogen albumin ratio and ischemic stroke during venoarterial extracorporeal membrane oxygenation. ASAIO J 2020; 66 (03) 277-282
• 43 Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A. ; Surgical Clinical Outcome REsearch (SCORE) Group. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015; 4 (06) e002066
• 44 Niebler RA, Parker H, Hoffman GM. Impact of anticoagulation and circuit technology on complications during extracorporeal membrane oxygenation. ASAIO J 2019; 65 (03) 270-276
• 45 Delmas C, Jacquemin A, Vardon-Bounes F. , et al. Anticoagulation monitoring under ECMO support: a comparative study between the activated coagulation time and the anti-Xa activity assay. J Intensive Care Med 2018; 1: 885066618776937
• 46 Leuquier L, Annich G, I'Brahim O. , et al. ELSO Anticoagulation Guideline 2014. Ann Arbor, MI: The Extracorporeal Life Support Organization (ELSO); 2014
• 47 Baluwala I, Favaloro EJ, Pasalic L. Therapeutic monitoring of unfractionated heparin - trials and tribulations. Expert Rev Hematol 2017; 10 (07) 595-605
• 48 Holbrook A, Schulman S, Witt DM. , et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e152S-e184S
• 49 Favaloro EJ, Bonar R, Aboud M. , et al; RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol 2005; 11 (03) 157-162
• 50 Brogan TV, Lequier L, Lorusso R, MacLaren G, Peek G. , eds. Extracorporeal Life Support: The ELSO Red Book, 5th ed. ELSO; 2017
• 51 Ryerson LM, Lequier LL. Anticoagulation management and monitoring during pediatric extracorporeal life support: a review of current issues. Front Pediatr 2016; 4: 67
• 52 Kuhle S, Eulmesekian P, Kavanagh B. , et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92 (04) 554-557
• 53 Ojito JW, Hannan RL, Burgos MM. , et al. Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution. J Extra Corpor Technol 2012; 44 (01) 15-20
• 54 Sarode K, Hussain SS, Tyroch A, Mukherjee D. A review of the current role of blood clotting analyzers in clinical practice. Cardiovasc Hematol Disord Drug Targets 2017; 17 (03) 167-179
• 55 Ranucci M, Di Dedda U, Baryshnikova E. Platelet contribution to clot strength in thromboelastometry: count, function, or both?. Platelets 2020; 31 (01) 88-93
• 56 Anderson L, Quasim I, Steven M. , et al. Interoperator and intraoperator variability of whole blood coagulation assays: a comparison of thromboelastography and rotational thromboelastometry. J Cardiothorac Vasc Anesth 2014; 28 (06) 1550-1557
• 57 Arnouk S, Altshuler D, Lewis TC. , et al. Evaluation of anti-Xa and activated partial thromboplastin time monitoring of heparin in adult patients receiving extracorporeal membrane oxygenation support. ASAIO J 2020; 66 (03) 300-306
• 58 McMichael ABV, Hornik CP, Hupp SR, Gordon SE, Ozment CP. Correlation among antifactor Xa, activated partial thromboplastin time, and heparin dose and association with pediatric Extracorporeal Membrane Oxygenation complications. ASAIO J 2020; 66 (03) 307-313
• 59 Henderson N, Sullivan JE, Myers J. , et al. Use of thromboelastography to predict thrombotic complications in pediatric and neonatal extracorporeal membraneous oxygenation. J Extra Corpor Technol 2018; 50 (03) 149-154
• 60 Hellmann C, Schmutz A, Kalbhenn J. Bleeding during veno-venous ECMO cannot reliably be predicted by rotational thrombelastometry (ROTEM™). Perfusion 2018; 33 (04) 289-296
• 61 Kessel AD, Kline M, Zinger M, McLaughlin D, Silver P, Sweberg TM. The impact and statistical analysis of a multifaceted anticoagulation strategy in children supported on ECMO: performance and pitfalls. J Intensive Care Med 2017; 32 (01) 59-67
• 62 Prakash S, Wiersema UF, Bihari S, Roxby D. Discordance between ROTEM® clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation. Anaesth Intensive Care 2016; 44 (01) 85-92
• 63 Panigada M, Iapichino G, L'Acqua C. , et al. Prevalence of “flat-line” thromboelastography during extracorporeal membrane oxygenation for respiratory failure in adults. ASAIO J 2016; 62 (03) 302-309
• 64 Panigada M, Artoni A, Passamonti SM. , et al. Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults. Minerva Anestesiol 2016; 82 (02) 170-179
• 65 Gilman EA, Koch CD, Santrach PJ, Schears GJ, Karon BS. Fresh and citrated whole-blood specimens can produce different thromboelastography results in patients on extracorporeal membrane oxygenation. Am J Clin Pathol 2013; 140 (02) 165-169
• 66 Bembea MM, Schwartz JM, Shah N. , et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013; 59 (01) 63-68
• 67 Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134 (06) 950-954
• 68 Nankervis CA, Preston TJ, Dysart KC. , et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53 (01) 111-114
• 69 Stammers AH, Willett L, Fristoe L. , et al. Coagulation monitoring during extracorporeal membrane oxygenation: the role of thrombelastography. J Extra Corpor Technol 1995; 27 (03) 137-145